INTERFERON ENHANCEMENT OF RADIOIMMUNOTHERAPY FOR COLON-CARCINOMA

Recombinant human gamma-interferon (IFN-gamma) has recently been shown to enhance localization of radiolabeled monoclonal antibodies (MAb) to human colon carcinoma xenografts in athymic mice. The present study investigates the ability of gamma-interferon to enhance radioimmunotherapy of a low carcinoembryonic antigen-expressing human colon cancer (WiDr) in athymic mice. Growth curve analysis, antibody localization, and dose estimation studies were performed. A significant tumor growth delay, measured as the time to reach 1.0 g, was noted for animals receiving specific anti-carcinoembryonic antigen Y-90-MAb (ZCE025, 120-mu-Ci) plus IFN-gamma (61.8 days) as compared to animals that received specific Y-90-MAb with phosphate-buffered saline (34.9 days; P < 0.005). IFN-gamma (100,000 units) was given i.p. every 8 h for 2 days before and 4 days after Y-90-MAb therapy. The time required to reach 1.0 g for animals treated with nonspecific Y-90-MAb (ZME018) was significantly less either with (38.3 days) or without (34.4 days) IFN-gamma. The difference was more apparent when compared to animals receiving IFN-gamma alone (30.0 days) or phosphate-buffered saline alone (28.9 days; P < 0.001). Increased antibody localization in the tumors of animals treated with IFN-gamma plus specific Y-90-MAb (43.2% injected dose/g) was seen in comparison to animals treated with specific Y-90-MAb without IFN-gamma (18.2% injected dose/g). The estimate of radiation dose delivered to the tumors, based on biodistribution data over time, revealed significantly higher levels in animals treated with specific Y-90-MAb with IFN-gamma (2477 cGy) compared to animals treated without IFN-gamma (1217 cGy). These results provide support for the use of gamma-interferon as an immunomodulating agent prior to radioimmunotherapy.